Nautilus Biotechnology (Nautilus Biotechnology) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Change In Receivables?

Nautilus Biotechnology's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Nautilus Biotechnology's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Nautilus Biotechnology's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Nautilus Biotechnology's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Nautilus Biotechnology's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nautilus Biotechnology's liquidation value for the three months ended in Mar. 2024 was $142.21 Mil.

Nautilus Biotechnology Change In Receivables Historical Data

The historical data trend for Nautilus Biotechnology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Change In Receivables Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Nautilus Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

Nautilus Biotechnology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Nautilus Biotechnology (NAS:NAUT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nautilus Biotechnology's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Nautilus Biotechnology's accounts receivable are only considered to be worth 75% of book value:

Nautilus Biotechnology's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	181.366	-	39.158	+	0.75 * 0	+	0.5 * 0
=	142.21

Nautilus Biotechnology Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website

https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Executives

Michael Seth Altman	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar	officer: Senior VP, Product Development	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld	officer: Chief People Officer	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry	officer: CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy	officer: General Counsel	C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel	director, 10 percent owner, officer: CEO, President, and Secretary	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin	officer: Senior VP, Operations	3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain	director	1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz	10 percent owner	2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen	10 percent owner	C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111